Intact PTH Detection Service

Analysis of intact parathyroid hormone (PTH) is useful in the diagnosis of hypercalcemia, hypocalcemia and hyperparathyroidism, besides it plays an important role in the prevention of bone mineral disorders in kidney patients. Creative BioMart Biomarker offers high quality detection service for intact PTH, ensuring high detection sensitivity and efficiency for each sample.


PTH is a polypeptide hormone secreted by the parathyroid glands that contains 84 amino acids. It mainly acts on bone and kidney. The secretion of PTH is in response to a decrease in serum calcium levels, which increases calcium levels in the blood by increasing the renal reabsorption of calcium. PTH has a dual effect on bone formation and bone resorption. Continuous large-doses PTH administration promotes bone resorption, and intermittent small-doses PTH administration promotes bone formation. Studies have shown that intermittent PTH administration promotes bone formation through two pathways in osteoblasts, one is to increase the number and surface of osteoblasts, and the other is to increase mineralized matrix deposition by affecting proliferation of precursors, inhibiting apoptosis, and activating lining cells. In osteocyte cell lines, PTH reduces the expression level of sclerostin which is mainly expressed in osteocytes as an inhibitor of Wnt signaling, thus PTH provides another paracrine mechanism that may stimulate osteoblast differentiation. Intact PTH is the second-generation immunoassays system for evaluating the activity of PTH in which both PTH (1-84) and PTH (7-84) fragments were detected. Intact PTH assays utilize two different monoclonal antibodies, one is a solid phase capture antibody directed against the C-terminal region of PTH, and the other is a detection antibody directed against the N -terminal region. The combination of these two antibodies makes intact PTH system considered to be more specific as they avoid cross-reactivity with C-terminal PTH fragments. It has improved relative to early monoclonal antibody surveillance by analyzing relevant clinical findings and is widely used in many clinical laboratories. Diseases due to too little or too much PTH, such as hypoparathyroidism, hyperparathyroidism and paraneoplastic syndrome, can cause bone disease, hypocalcemia and hypercalcemia, and intact PTH is a widely used PTH detection system, therefore, intact PTH detection is essential for bone pathophysiology and disease research.

Intact PTH Detection ServiceFigure 1. Parathyroid hormone assay (Kakuta, et al. 2018)

Application of Intact PTH Detection

  • Plasma and serum intact PTH levels as biomarkers to predict different diseases, such as hypoparathyroidism, hyperparathyroidism, hypocalcemia, hypercalcemia, osteoporosis, etc.

Our Advantages

  • Guarantee high accuracy and sensitivity for intact PTH detection
  • Ensure high repeatability of intact PTH detection
  • Short turn-around time of detection service
  • Competitive price in the market of detection services
  • Accept a wide range of sample types (serum and EDTA plasma)

Detection Technologies


Workflow of Intact PTH Detection at Creative BioMart Biomarker

Creative BioMart Biomarker strictly controls each specific experimental step in the intact PTH detection procedure to ensure accurately quantify the level of PTH in each sample.

Intact PTH Detection Service

At Creative BioMart Biomarker, we not only provide high-quality intact PTH detection service, but also provide detection services for other biomarkers. You can communicate with our experts according to your research needs, and we will determine the final detection technological scheme based on the communication results. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.


  1. Kim, J. H.; et al. Intermittent PTH administration improves alveolar bone formation in type 1 diabetic rats with periodontitis. Journal of Translational Medicine. 2018, 16(1): 70.
  2. Koda, R.; et al. Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy. Clinical & Experimental Nephrology. 2015, 19(4): 710-717.
  3. Couchman, L.; et al. LC-MS candidate reference methods for the harmonisation of parathyroid hormone (PTH) measurement: a review of recent developments and future considerations. Clinical Chemistry and Laboratory Medicine. 2014, 52(9): 1251-1263.
  4. Kakuta, T.; et al. Critical governance issue of parathyroid hormone assays and its selection in the management of chronic kidney disease mineral and bone disorders. Therapeutic Apheresis and Dialysis. 2018, 22(Suppl 3).


Contact Us


Enter your email here to subscribe